Ionis Pharmaceuticals, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
Ionis Pharmaceuticals, Inc. (IONS) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $170.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2020-11-04
- 2020-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $170.00K.
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $192.00K.
- 2020-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $4.84M.
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $296.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2020-09-30 | $170.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $192.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $4.84M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $296.00K 10-K · filed 2020-03-02 |
| 2019-09-30 | $579.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $712.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.36M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $4.07M 10-K · filed 2019-03-01 |
| 2018-09-30 | $3.94M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $4.09M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $4.60M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $3.07M 10-K · filed 2018-02-28 |
| 2017-09-30 | $1.56M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $1.73M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.86M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $2.01M 10-K · filed 2017-03-01 |
| 2016-09-30 | $1.12M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.20M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $670.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $2.55M 10-K · filed 2016-02-26 |
| 2015-09-30 | $977.00K 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |